Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186172 | 0.86 | TDP1 (0.52) | CHRNB2CHRNA4KMT2ATRPM8ALDH1A1 | |
| SCHEMBL12277668 | 0.86 | RIPK1 (0.59) | CHRNB2CHRNA4KMT2AALDH1A1RIPK1 | |
| SCHEMBL2187051 | 0.81 | KDM4E (0.61) | CHRNB2CHRNA4KMT2ATRPM8ALDH1A1 | |
| SCHEMBL4018145 | 0.79 | LMNA (0.56) | KMT2AALDH1A1MEN1HTTLMNA | |
| SCHEMBL12277694 | 0.78 | CHRNA7 (0.53) | RIPK1 | |
| SCHEMBL14276916 | 0.78 | SMN1; SMN2 (0.51) | CHRNB2CHRNA4KMT2ATRPM8ALDH1A1 | |
| SCHEMBL20057648 | 0.77 | CHRNB2 (0.60) | CHRNB2CHRNA4KMT2ATRPM8ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27841922 | 0.77 | NAPRT (0.61) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL31336442 | 0.77 | KMT2A (0.58) | KMT2ATRPM8ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2188785 | 0.77 | TDP1 (0.58) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | claimed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | claimed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | claimed |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | CYP2A6, CYP2B6, CYP2A13 | CHRNB2 1165/4885CHRNA4 1366/4885KMT2A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.